Northwestern Mutual Wealth Management Co. Has $58,000 Stake in Haemonetics Co. (NYSE:HAE)

Northwestern Mutual Wealth Management Co. reduced its holdings in shares of Haemonetics Co. (NYSE:HAE) by 18.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 704 shares of the medical instruments supplier’s stock after selling 161 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Haemonetics were worth $58,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in HAE. Capital Research Global Investors boosted its position in shares of Haemonetics by 2.3% during the 1st quarter. Capital Research Global Investors now owns 6,674,751 shares of the medical instruments supplier’s stock valued at $569,690,000 after purchasing an additional 151,183 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Haemonetics by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 5,406,309 shares of the medical instruments supplier’s stock valued at $462,293,000 after acquiring an additional 25,451 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Haemonetics by 3.2% during the 4th quarter. Wellington Management Group LLP now owns 3,268,083 shares of the medical instruments supplier’s stock valued at $279,454,000 after acquiring an additional 101,029 shares during the period. Dimensional Fund Advisors LP boosted its stake in Haemonetics by 6.3% during the second quarter. Dimensional Fund Advisors LP now owns 978,735 shares of the medical instruments supplier’s stock worth $80,972,000 after acquiring an additional 57,665 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its holdings in Haemonetics by 6,573.6% in the second quarter. Thrivent Financial for Lutherans now owns 849,350 shares of the medical instruments supplier’s stock worth $70,267,000 after purchasing an additional 836,623 shares during the period. 99.67% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Haemonetics news, insider Stewart W. Strong sold 4,312 shares of the company’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $91.15, for a total value of $393,038.80. Following the completion of the transaction, the insider now owns 18,196 shares in the company, valued at $1,658,565.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on HAE. JMP Securities reissued a “market outperform” rating and set a $125.00 price objective on shares of Haemonetics in a research report on Tuesday, August 13th. Barrington Research reissued an “outperform” rating and issued a $108.00 price target on shares of Haemonetics in a research report on Monday, September 23rd. CL King started coverage on shares of Haemonetics in a report on Friday, September 13th. They set a “buy” rating and a $116.00 price objective on the stock. BTIG Research started coverage on shares of Haemonetics in a report on Tuesday, September 10th. They set a “buy” rating and a $112.00 price objective for the company. Finally, Bank of America started coverage on shares of Haemonetics in a research report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 target price for the company. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Haemonetics currently has a consensus rating of “Moderate Buy” and a consensus price target of $106.14.

Haemonetics Stock Performance

NYSE HAE opened at $74.97 on Friday. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.76 and a quick ratio of 2.33. The company has a fifty day moving average price of $76.33 and a 200-day moving average price of $83.88. Haemonetics Co. has a 1 year low of $70.74 and a 1 year high of $97.97. The firm has a market cap of $3.82 billion, a price-to-earnings ratio of 32.74, a PEG ratio of 1.19 and a beta of 0.30.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing the consensus estimate of $1.03 by ($0.01). Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The firm had revenue of $336.17 million during the quarter, compared to analysts’ expectations of $335.08 million. During the same quarter last year, the business posted $1.05 EPS. The company’s quarterly revenue was up 8.0% on a year-over-year basis. As a group, equities research analysts predict that Haemonetics Co. will post 4.57 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.